Travaux scientifiques

Prof. Dr. Fahriye Tuğba Köş

109 publications. La source de l’information est indiquée à côté de chaque publication.

Retour au profil

  1. MEtaStatik pRoStat kaRSinoMlu HaStalaRda SağkalIM analizi vE pRognoStik FaktöRlER; tEk MERkEz dEnEyiMi

    AYBU AVESIS, 2017

    Source : OpenAlex

  2. Evaluation of the effects of red blood cell distribution width on survival in lung cancer patients

    Współczesna Onkologia, 2016

    DOI 10.5114/wo.2016.60072 PMID 27358595 19 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  3. Prognostic role of pretreatment platelet/lymphocyte ratio in patients with non-small cell lung cancer

    Wiener Klinische Wochenschrift, 2016

    DOI 10.1007/s00508-015-0724-8 PMID 25720573 28 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  4. Böbrek Hücreli Karsinomlu Hastaların Demografik Özellikleri ve Tedavi Sonuçları: Tek Merkez Deneyimi

    Ankara Medical Journal, 2016

    DOI 10.17098/amj.61112 1 citation (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  5. Duodenal adenocarcinoma: A rare cause of chyloperitoneum (chylous ascites)

    Indian Journal of Cancer, 2015

    DOI 10.4103/0019-509x.175565 PMID 26837993 Source : ORCID

  6. Hypersensitivity and tumor lysis syndrome associated with cetuximab treatment: Should we be afraid?

    Tumori, 2015

    DOI 10.5301/tj.5000246 PMID 25721679 2 citations (Europe PMC) Source : ORCID

  7. 2292 The prognostic significance of neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and prognostic nutritional index in metastatic pancreas cancer

    European Journal of Cancer, 2015

    DOI 10.1016/s0959-8049(16)31208-4 1 citation (OpenAlex) Source : OpenAlex

  8. Assessment of Prognostic Value of "Neutrophil to Lymphocyte Ratio" and "Prognostic Nutritional Index" as a Sytemic Inflammatory Marker in Non-small Cell Lung Cancer

    Asian Pacific Journal of Cancer Prevention, 2015

    DOI 10.7314/apjcp.2015.16.9.3997 PMID 25987075 42 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  9. Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio associated with prognosis in patients with HER2-positive early breast cancer receiving adjuvant trastuzumab?

    Journal of B.U.ON. : official journal of the Balkan Union of Oncology, 2015

    PMID 26214622 36 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  10. Patients with HER2-positive Early Breast Cancer Receiving Adjuvant Trastuzumab: Clinicopathological Features, Efficacy, and Factors Affecting Survival

    Asian Pacific Journal of Cancer Prevention, 2015

    DOI 10.7314/apjcp.2015.16.4.1643 PMID 25743846 2 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  11. ASSOCIATION BETWEEN BLOOD UREA NITROGEN/ALBUMIN RATIO AND PROGNOSIS IN NON-SMALL CELL LUNG CANCER

    Acta Medica Mediterranea, 2015

    Source : ORCID

  12. Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio associated with prognosis in patients with HER2-positive early breast cancer receiving adjuvant trastuzumab?

    Journal of B.U.ON., 2015

    Source : ORCID

  13. Comparison of Serum Lipid Levels in Chronic Obstructive Pulmonary Disease and Lung Cancer

    Journal of Clinical and Analytical Medicine, 2015

    DOI 10.4328/jcam.3182 Texte intégral en libre accèsSource : ORCID

  14. Helicobacter Pylori Seropostivity of Colon Cancer

    Journal of Clinical and Analytical Medicine, 2015

    DOI 10.4328/jcam.1826 Source : ORCID

  15. Primary Retroperitoneal Mucinous Cystadenocarcinoma: 5th Male Case in the Literature

    Journal of Clinical and Analytical Medicine, 2015

    DOI 10.4328/jcam.1381 Source : ORCID

  16. Prognostic Factors and Adjuvant Treatments for Surgically Treated Cancers of the Biliary Tract: A Multicentre Study of the Anatolian Society of Medical Oncology (ASMO)

    Asian Pacific Journal of Cancer Prevention, 2014

    DOI 10.7314/apjcp.2014.15.22.9687 PMID 25520089 1 citation (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  17. Adjuvant chemotherapy outcomes in patients over 65 years with early stage colorectal carcinoma.

    Journal of B.U.ON. : official journal of the Balkan Union of Oncology, 2014

    PMID 25536594 Texte intégral en libre accèsSource : ORCID

  18. Adjuvant chemotherapy outcomes in patients over 65 years with early stage colorectal carcinoma

    Journal of B.U.ON., 2014

    Source : ORCID

  19. Evaluation of the effect of comorbidity on survival in pancreatic cancer by using "Charlson Comorbidity Index" and "Cumulative Illness Rating Scale"

    Wiener Klinische Wochenschrift, 2014

    DOI 10.1007/s00508-013-0453-9 PMID 24249323 12 citations (Europe PMC) Source : ORCID

  20. Serum 25-hydroxy Vitamin D Status is Not Related to Osteopenia/Osteoporosis Risk in Colorectal Cancer Survivors

    Asian Pacific Journal of Cancer Prevention, 2014

    DOI 10.7314/apjcp.2014.15.8.3377 PMID 24870725 1 citation (Europe PMC) Texte intégral en libre accèsSource : ORCID

  21. Treatment and Outcomes of Ewing Sarcoma in Turkish Adults: A Single Centre Experience

    Asian Pacific Journal of Cancer Prevention, 2014

    DOI 10.7314/apjcp.2014.15.1.327 PMID 24528050 10 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  22. Results of adjuvant FOLFOX regimens in stage III colorectal cancer patients: Retrospective analysis of 667 patients anatolian society of medical oncology

    Oncology (Switzerland), 2013

    DOI 10.1159/000336902 PMID 23392240 14 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  23. Variations in tumor marker levels in metastatic breast cancer patients according to tumor subtypes.

    Journal of B.U.ON. : official journal of the Balkan Union of Oncology, 2013

    PMID 24065471 6 citations (Europe PMC) Source : ORCID

  24. Administration of contrast media just before cisplatin-based chemotherapy increases cisplatin-induced nephrotoxicity.

    Journal of B.U.ON. : official journal of the Balkan Union of Oncology, 2013

    PMID 23613416 11 citations (Europe PMC) Source : ORCID

  25. Administration of contrast media just before cisplatin-based chemotherapy increases cisplatin-induced nephrotoxicity

    Journal of B.U.ON., 2013

    Source : ORCID

  26. DEMOGRAPHIC FEATURES AND FACTORS AFFECTING OVERALL SURVIVAL IN PATIENTS WITH HEPATOCELLULAR CARCINOMA: A RETROSPECTIVE ANALYSIS IN TURKEY

    Acta Medica Mediterranea, 2013

    Source : ORCID

  27. Evaluation of Renal Function Using the Level of Neutrophil Gelatinase-Associated Lipocalin is Not Predictive of Nephrotoxicity Associated with Cisplatin-Based Chemotherapy

    Asian Pacific Journal of Cancer Prevention, 2013

    DOI 10.7314/apjcp.2013.14.2.1111 PMID 23621196 5 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  28. Evaluation of the Renal Function Using Cystatin C Level in the Patients Receiving Cisplatin-Based Chemotherapy

    Renal Failure, 2013

    DOI 10.3109/0886022x.2013.777929 PMID 23530579 11 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  29. Evaluation of vitamin D status and risk factors of osteopenia/osteoporosis in colorectal cancer survivors

    European Journal of Cancer, 2013

    Source : ORCID

  30. Variations in tumor marker levels in metastatic breast cancer patients according to tumor subtypes

    Journal of B.U.ON., 2013

    Source : ORCID

  31. Pages 46-48

    Kırıkkale University Institutional Repository, 2013

    DOI 10.24938/kutfd.124757 Texte intégral en libre accèsSource : OpenAlex

  32. Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine alone or gemcitabine plus cisplatin: retrospective analysis of a multicenter study.

    PubMed, 2012

    PMID 22517701 16 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  33. Gemcitabine Alone versus combination of Gemcitabine and Cisplatin for the Treatment of Patients with Locally Advanced and/or Metastatic Pancreatic Carcinoma: A Retrospective Analysis of multicenter study (Anatolian Society of Medical Oncology)

    Neoplasma, 2012

    DOI 10.4149/neo_2012_038 PMID 22329849 12 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  34. Isolated testicular metastasis of gastric cancer

    Journal of Gastrointestinal Cancer, 2012

    DOI 10.1007/s12029-011-9305-x PMID 21761128 2 citations (Europe PMC) Source : ORCID

  35. Multiple primary malignant neoplasms: multi-center results from Turkey.

    Journal of B.U.ON. : official journal of the Balkan Union of Oncology, 2012

    PMID 23335539 21 citations (Europe PMC) Source : ORCID

  36. Administration of contrast media just before the cisplatin-based chemotherapy increases the cisplatin-induced nephrotoxicity

    Journal of Clinical Oncology, 2012

    DOI 10.1200/jco.2012.30.15_suppl.e13031 12 citations (OpenAlex) Source : ORCID

  37. Is There an Association between Blood Group and Survival in Pancreatic Cancer?

    Asian Pacific Journal of Cancer Prevention, 2012

    DOI 10.7314/apjcp.2012.13.12.6151 PMID 23464421 7 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  38. Long Term Survivors with Metastatic Pancreatic Cancer Treated with Gemcitabine Alone or Plus Cisplatin: a Retrospective Analysis of an Anatolian Society of Medical Oncology Multicenter Study

    Asian Pacific Journal of Cancer Prevention, 2012

    DOI 10.7314/apjcp.2012.13.5.1841 PMID 22901133 8 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  39. Multiple primary malignant neoplasms: Multi-center results from Turkey

    Journal of B.U.ON., 2012

    Source : ORCID

  40. Primary anorectal malignant melanoma: rare but highly lethal malignancy

    Turkish Journal of Medical Sciences, 2012

    DOI 10.3906/sag-1202-62 2 citations (OpenAlex) Texte intégral en libre accèsSource : ORCID

  41. Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine alone or gemcitabine plus cisplatin: retrospective analysis of a multicenter study

    Journal of B.U.ON., 2012

    Source : ORCID

  42. Adjuvant therapy for gallbladder and bile duct cancers: retrospective comparative study.

    Journal of B.U.ON. : official journal of the Balkan Union of Oncology, 2011

    PMID 22006751 2 citations (Europe PMC) Source : ORCID

  43. Safety and efficacy of FOLFIRI-bevacizumab for metastatic colorectal carcinoma as second line treatment.

    Journal of B.U.ON. : official journal of the Balkan Union of Oncology, 2011

    PMID 22006750 4 citations (Europe PMC) Source : ORCID

  44. Long term survival in a metastatic alveolar soft part sarcoma at the time of diagnosis: a case with 17 years of follow-up.

    Journal of B.U.ON. : official journal of the Balkan Union of Oncology, 2011

    PMID 21766518 2 citations (Europe PMC) Source : ORCID

  45. ADJUVANT THERAPY FOR GALL BLADDER AND BILE DUCT CANCERS: RETROSPECTIVE COMPARATIVE STUDY

    Annals of Oncology, 2011

    Source : ORCID

  46. Adjuvant therapy for gallbladder and bile duct cancers: retrospective comparative study

    Journal of B.U.ON., 2011

    Source : ORCID

  47. Comparison of Cisplatin-5-Fluorouracil-Folinic Acid versus Modified Docetaxel-Cisplatin-5-Fluorouracil Regimens in the First-Line Treatment of Metastatic Gastric Cancer

    Chemotherapy, 2011

    DOI 10.1159/000327840 PMID 21597287 14 citations (Europe PMC) Source : ORCID

  48. Gemcitabine and cisplatin in patients with carcinoma of unknown primary site

    Medical Oncology, 2011

    DOI 10.1007/s12032-010-9465-8 PMID 20300978 Source : ORCID

  49. HELICOBACTER PYLORI SEROPOSITIVITY IN COLORECTAL CANCER PATIENTS

    Annals of Oncology, 2011

    Source : ORCID

  50. Long term survival in a metastatic alveolar soft part sarcoma at the time of diagnosis: a case with 17 years of follow-up

    Journal of B.U.ON., 2011

    Source : ORCID